JP2008524236A - エストロゲンβアゴニストについての新規用途 - Google Patents
エストロゲンβアゴニストについての新規用途 Download PDFInfo
- Publication number
- JP2008524236A JP2008524236A JP2007546887A JP2007546887A JP2008524236A JP 2008524236 A JP2008524236 A JP 2008524236A JP 2007546887 A JP2007546887 A JP 2007546887A JP 2007546887 A JP2007546887 A JP 2007546887A JP 2008524236 A JP2008524236 A JP 2008524236A
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- alkyl
- halogen
- hydroxyphenyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940011871 estrogen Drugs 0.000 title abstract description 40
- 239000000262 estrogen Substances 0.000 title abstract description 40
- 229940125388 beta agonist Drugs 0.000 title description 4
- 208000024891 symptom Diseases 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 72
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 213
- 150000002367 halogens Chemical class 0.000 claims description 93
- 229910052736 halogen Inorganic materials 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 78
- 125000003342 alkenyl group Chemical group 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 62
- 150000002431 hydrogen Chemical class 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 49
- 239000003446 ligand Substances 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- -1 —CHO Chemical group 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 43
- 201000000980 schizophrenia Diseases 0.000 claims description 43
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000000304 alkynyl group Chemical group 0.000 claims description 35
- 208000018737 Parkinson disease Diseases 0.000 claims description 30
- 208000019901 Anxiety disease Diseases 0.000 claims description 29
- 229940002612 prodrug Drugs 0.000 claims description 29
- 239000000651 prodrug Substances 0.000 claims description 29
- 230000036506 anxiety Effects 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 230000015654 memory Effects 0.000 claims description 20
- 201000006417 multiple sclerosis Diseases 0.000 claims description 20
- 208000024827 Alzheimer disease Diseases 0.000 claims description 19
- 208000006011 Stroke Diseases 0.000 claims description 19
- 239000005557 antagonist Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 206010033799 Paralysis Diseases 0.000 claims description 12
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 206010044565 Tremor Diseases 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 206010003591 Ataxia Diseases 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 206010016256 fatigue Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 230000011514 reflex Effects 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 201000007201 aphasia Diseases 0.000 claims description 7
- 230000006399 behavior Effects 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 208000002173 dizziness Diseases 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 230000003936 working memory Effects 0.000 claims description 7
- 206010010144 Completed suicide Diseases 0.000 claims description 6
- 206010012239 Delusion Diseases 0.000 claims description 6
- 208000003164 Diplopia Diseases 0.000 claims description 6
- 208000004547 Hallucinations Diseases 0.000 claims description 6
- 206010019468 Hemiplegia Diseases 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 231100000868 delusion Toxicity 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 230000033001 locomotion Effects 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 206010029864 nystagmus Diseases 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 230000002996 emotional effect Effects 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 230000008449 language Effects 0.000 claims description 5
- 206010027175 memory impairment Diseases 0.000 claims description 5
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 5
- 230000035900 sweating Effects 0.000 claims description 5
- 230000000946 synaptic effect Effects 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 5
- 206010008479 Chest Pain Diseases 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 4
- 206010011971 Decreased interest Diseases 0.000 claims description 4
- 206010013887 Dysarthria Diseases 0.000 claims description 4
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 4
- 208000004044 Hypesthesia Diseases 0.000 claims description 4
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- 230000037007 arousal Effects 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 4
- 238000004880 explosion Methods 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 208000034783 hypoesthesia Diseases 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 230000007787 long-term memory Effects 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 231100000862 numbness Toxicity 0.000 claims description 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 4
- 230000035807 sensation Effects 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 208000018198 spasticity Diseases 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 206010033864 Paranoia Diseases 0.000 claims description 3
- 208000027099 Paranoid disease Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010042464 Suicide attempt Diseases 0.000 claims description 3
- 230000006978 adaptation Effects 0.000 claims description 3
- 230000003542 behavioural effect Effects 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 3
- 208000029444 double vision Diseases 0.000 claims description 3
- 230000010365 information processing Effects 0.000 claims description 3
- 230000008450 motivation Effects 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- LKNGKJDCKVVOLK-UHFFFAOYSA-N 1,5-dichloro-8-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC(F)=C(C(Cl)=C(O)C=C2)C2=C1Cl LKNGKJDCKVVOLK-UHFFFAOYSA-N 0.000 claims description 2
- YTFVBUBYMJJWQZ-UHFFFAOYSA-N 1,8-dichloro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC(Cl)=C(C(Cl)=C(O)C=C2)C2=C1 YTFVBUBYMJJWQZ-UHFFFAOYSA-N 0.000 claims description 2
- IPBYYNRPJBGKET-UHFFFAOYSA-N 1-bromo-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(Br)=C(O)C=C2)C2=C1 IPBYYNRPJBGKET-UHFFFAOYSA-N 0.000 claims description 2
- DZNMJDCCSRLHNP-UHFFFAOYSA-N 1-chloro-6-(2,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=C(F)C(O)=CC(F)=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 DZNMJDCCSRLHNP-UHFFFAOYSA-N 0.000 claims description 2
- LIGCNYLVJJWYIY-UHFFFAOYSA-N 1-chloro-6-(2,6-difluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound FC1=CC(O)=CC(F)=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 LIGCNYLVJJWYIY-UHFFFAOYSA-N 0.000 claims description 2
- LSVPDXDJCFTDSL-UHFFFAOYSA-N 1-chloro-6-(2-chloro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound ClC1=CC(O)=CC=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 LSVPDXDJCFTDSL-UHFFFAOYSA-N 0.000 claims description 2
- AHELSLCUIPWEII-UHFFFAOYSA-N 1-chloro-6-(3,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC2=C(Cl)C(O)=CC=C2C=C1C1=CC(F)=C(O)C(F)=C1 AHELSLCUIPWEII-UHFFFAOYSA-N 0.000 claims description 2
- FWRUMAVROMTQMY-UHFFFAOYSA-N 1-chloro-6-(3-chloro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=C(Cl)C(O)=CC=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 FWRUMAVROMTQMY-UHFFFAOYSA-N 0.000 claims description 2
- HZPYQCSGTTZVLW-UHFFFAOYSA-N 1-chloro-6-(3-fluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=C(F)C(O)=CC=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 HZPYQCSGTTZVLW-UHFFFAOYSA-N 0.000 claims description 2
- GGWIHGXEDCXOIL-UHFFFAOYSA-N 1-chloro-6-(4-hydroxy-2-methylphenyl)naphthalen-2-ol Chemical compound CC1=CC(O)=CC=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 GGWIHGXEDCXOIL-UHFFFAOYSA-N 0.000 claims description 2
- YHEHVRSGKUYDON-UHFFFAOYSA-N 1-chloro-6-(4-hydroxyphenyl)-2-naphthol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 YHEHVRSGKUYDON-UHFFFAOYSA-N 0.000 claims description 2
- IPEUQNVORWKWRB-UHFFFAOYSA-N 1-chloro-6-phenylnaphthalen-2-ol Chemical compound C1=CC2=C(Cl)C(O)=CC=C2C=C1C1=CC=CC=C1 IPEUQNVORWKWRB-UHFFFAOYSA-N 0.000 claims description 2
- DXLDXLIYYQFLKD-UHFFFAOYSA-N 1-chloro-8-fluoro-6-(3-fluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=C(F)C(O)=CC=C1C1=CC(F)=C(C(Cl)=C(O)C=C2)C2=C1 DXLDXLIYYQFLKD-UHFFFAOYSA-N 0.000 claims description 2
- VQATUPWMFYRKSD-UHFFFAOYSA-N 1-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(F)=C(O)C=C2)C2=C1 VQATUPWMFYRKSD-UHFFFAOYSA-N 0.000 claims description 2
- MQIMZDXIAHJKQP-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol Chemical compound N=1C2=CC(O)=CC(C=C)=C2OC=1C1=CC=C(O)C(F)=C1 MQIMZDXIAHJKQP-UHFFFAOYSA-N 0.000 claims description 2
- NLFWTSXMRSTIKQ-UHFFFAOYSA-N 2-chloro-4-naphthalen-2-ylphenol Chemical compound C1=C(Cl)C(O)=CC=C1C1=CC=C(C=CC=C2)C2=C1 NLFWTSXMRSTIKQ-UHFFFAOYSA-N 0.000 claims description 2
- JZAALJHRGIVUQB-UHFFFAOYSA-N 2-fluoro-4-naphthalen-2-ylphenol Chemical compound C1=C(F)C(O)=CC=C1C1=CC=C(C=CC=C2)C2=C1 JZAALJHRGIVUQB-UHFFFAOYSA-N 0.000 claims description 2
- QZUOTBJDFQFRGT-UHFFFAOYSA-N 2-hydroxy-6-(4-hydroxyphenyl)naphthalene-1-carbonitrile Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(C#N)=C(O)C=C2)C2=C1 QZUOTBJDFQFRGT-UHFFFAOYSA-N 0.000 claims description 2
- NTESIIXLFNAOOM-UHFFFAOYSA-N 3-(3,5-difluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile Chemical compound C1=C(C#N)C2=CC(O)=CC=C2C=C1C1=CC(F)=C(O)C(F)=C1 NTESIIXLFNAOOM-UHFFFAOYSA-N 0.000 claims description 2
- NSSOSHDCWCMNDM-UHFFFAOYSA-N 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile Chemical compound C1=C(C#N)C2=CC(O)=CC=C2C=C1C1=CC=C(O)C(F)=C1 NSSOSHDCWCMNDM-UHFFFAOYSA-N 0.000 claims description 2
- SCURDNNVFUOCIP-UHFFFAOYSA-N 3-bromo-1,8-dichloro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC(Cl)=C(C(Cl)=C(O)C(Br)=C2)C2=C1 SCURDNNVFUOCIP-UHFFFAOYSA-N 0.000 claims description 2
- RIQUETWHZUIZKU-UHFFFAOYSA-N 3-bromo-8-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC(Cl)=C(C=C(O)C(Br)=C2)C2=C1 RIQUETWHZUIZKU-UHFFFAOYSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- AUZLISXBMGKYGA-UHFFFAOYSA-N 6-(2,6-difluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC2=CC(O)=CC=C2C=C1C1=C(F)C=C(O)C=C1F AUZLISXBMGKYGA-UHFFFAOYSA-N 0.000 claims description 2
- FNSIACDWDZGUHN-UHFFFAOYSA-N 6-(2-chloro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound ClC1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1 FNSIACDWDZGUHN-UHFFFAOYSA-N 0.000 claims description 2
- MAFQDFZNSVYFEW-UHFFFAOYSA-N 6-(2-fluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound FC1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1 MAFQDFZNSVYFEW-UHFFFAOYSA-N 0.000 claims description 2
- BXIITHSNGXGDCN-UHFFFAOYSA-N 6-(3-chlorophenyl)naphthalen-2-ol Chemical compound C1=CC2=CC(O)=CC=C2C=C1C1=CC=CC(Cl)=C1 BXIITHSNGXGDCN-UHFFFAOYSA-N 0.000 claims description 2
- QTDYCKGQBCKMGC-UHFFFAOYSA-N 6-(3-fluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC2=CC(O)=CC=C2C=C1C1=CC=C(O)C(F)=C1 QTDYCKGQBCKMGC-UHFFFAOYSA-N 0.000 claims description 2
- VHWBXEUHUQDHDH-UHFFFAOYSA-N 6-(3-hydroxyphenyl)naphthalen-2-ol Chemical compound OC1=CC=CC(C=2C=C3C=CC(O)=CC3=CC=2)=C1 VHWBXEUHUQDHDH-UHFFFAOYSA-N 0.000 claims description 2
- TWSSGPRRAGPVKD-UHFFFAOYSA-N 6-(4-hydroxy-2-methoxyphenyl)naphthalen-2-ol Chemical compound COC1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1 TWSSGPRRAGPVKD-UHFFFAOYSA-N 0.000 claims description 2
- FGIUXCLAHODWKV-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-1-methylnaphthalen-2-ol Chemical compound C=1C=C2C(C)=C(O)C=CC2=CC=1C1=CC=C(O)C=C1 FGIUXCLAHODWKV-UHFFFAOYSA-N 0.000 claims description 2
- MYVOVZDBAWARDP-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-1-nitronaphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(=C(O)C=C2)[N+]([O-])=O)C2=C1 MYVOVZDBAWARDP-UHFFFAOYSA-N 0.000 claims description 2
- INNGVLJQICTRAF-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-1-phenylnaphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(=C(O)C=C2)C=3C=CC=CC=3)C2=C1 INNGVLJQICTRAF-UHFFFAOYSA-N 0.000 claims description 2
- VEQWNMMVQWDERW-UHFFFAOYSA-N 7-(3-hydroxyphenyl)naphthalen-2-ol Chemical compound OC1=CC=CC(C=2C=C3C=C(O)C=CC3=CC=2)=C1 VEQWNMMVQWDERW-UHFFFAOYSA-N 0.000 claims description 2
- NSCZTZNRMFWAIY-UHFFFAOYSA-N 7-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=CC(O)=C2)C2=C1 NSCZTZNRMFWAIY-UHFFFAOYSA-N 0.000 claims description 2
- AOWCVRXIHIHAPN-UHFFFAOYSA-N 7-hydroxy-3-(4-hydroxyphenyl)naphthalene-1-carbonitrile Chemical compound C1=CC(O)=CC=C1C1=CC(C#N)=C(C=C(O)C=C2)C2=C1 AOWCVRXIHIHAPN-UHFFFAOYSA-N 0.000 claims description 2
- XSODNSMEBNRYBI-UHFFFAOYSA-N 8-bromo-7-hydroxy-3-(4-hydroxyphenyl)naphthalene-1-carbonitrile Chemical compound C1=CC(O)=CC=C1C1=CC(C#N)=C(C(Br)=C(O)C=C2)C2=C1 XSODNSMEBNRYBI-UHFFFAOYSA-N 0.000 claims description 2
- DGVWRZXKKCDNLS-UHFFFAOYSA-N 8-chloro-3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile Chemical compound C1=C(F)C(O)=CC=C1C1=CC(C#N)=C(C(Cl)=C(O)C=C2)C2=C1 DGVWRZXKKCDNLS-UHFFFAOYSA-N 0.000 claims description 2
- IVJIWGTXXHDRCU-UHFFFAOYSA-N 8-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC(Cl)=C(C=C(O)C=C2)C2=C1 IVJIWGTXXHDRCU-UHFFFAOYSA-N 0.000 claims description 2
- ZOCBCFXUQAYMNS-UHFFFAOYSA-N 8-chloro-7-hydroxy-3-(4-hydroxyphenyl)naphthalene-1-carbonitrile Chemical compound C1=CC(O)=CC=C1C1=CC(C#N)=C(C(Cl)=C(O)C=C2)C2=C1 ZOCBCFXUQAYMNS-UHFFFAOYSA-N 0.000 claims description 2
- KBQSRNQTSRTYGN-UHFFFAOYSA-N 8-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC(F)=C(C=C(O)C=C2)C2=C1 KBQSRNQTSRTYGN-UHFFFAOYSA-N 0.000 claims description 2
- 208000000187 Abnormal Reflex Diseases 0.000 claims description 2
- 206010054196 Affect lability Diseases 0.000 claims description 2
- 206010003497 Asphyxia Diseases 0.000 claims description 2
- 206010048994 Bladder spasm Diseases 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 2
- 206010008469 Chest discomfort Diseases 0.000 claims description 2
- 206010009346 Clonus Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 241001539473 Euphoria Species 0.000 claims description 2
- 206010015535 Euphoric mood Diseases 0.000 claims description 2
- 206010015958 Eye pain Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010021118 Hypotonia Diseases 0.000 claims description 2
- 206010021703 Indifference Diseases 0.000 claims description 2
- 206010022520 Intention tremor Diseases 0.000 claims description 2
- 206010027940 Mood altered Diseases 0.000 claims description 2
- 206010027951 Mood swings Diseases 0.000 claims description 2
- 208000007379 Muscle Hypotonia Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000002033 Myoclonus Diseases 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- 206010029412 Nightmare Diseases 0.000 claims description 2
- 206010029897 Obsessive thoughts Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 claims description 2
- 206010033885 Paraparesis Diseases 0.000 claims description 2
- 206010033892 Paraplegia Diseases 0.000 claims description 2
- 206010034719 Personality change Diseases 0.000 claims description 2
- 206010038967 Retrograde ejaculation Diseases 0.000 claims description 2
- 206010040021 Sensory abnormalities Diseases 0.000 claims description 2
- 206010040030 Sensory loss Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 230000016571 aggressive behavior Effects 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 125000003435 aroyl group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000004456 color vision Effects 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 206010013990 dysuria Diseases 0.000 claims description 2
- 230000008451 emotion Effects 0.000 claims description 2
- 230000004424 eye movement Effects 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 230000008921 facial expression Effects 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 208000018883 loss of balance Diseases 0.000 claims description 2
- 230000027939 micturition Effects 0.000 claims description 2
- 230000007510 mood change Effects 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 230000002981 neuropathic effect Effects 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 208000035824 paresthesia Diseases 0.000 claims description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 2
- 230000000272 proprioceptive effect Effects 0.000 claims description 2
- 208000022749 pupil disease Diseases 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims description 2
- 230000001020 rhythmical effect Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 208000013220 shortness of breath Diseases 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 230000009747 swallowing Effects 0.000 claims description 2
- 206010042772 syncope Diseases 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 208000021090 palsy Diseases 0.000 claims 2
- XIWROJLPONIAKV-UHFFFAOYSA-N 1-chloro-6-(2-fluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound FC1=CC(O)=CC=C1C1=CC=C(C(Cl)=C(O)C=C2)C2=C1 XIWROJLPONIAKV-UHFFFAOYSA-N 0.000 claims 1
- OYUGBGZDLCAQEA-UHFFFAOYSA-N 1-chloro-8-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC(F)=C(C(Cl)=C(O)C=C2)C2=C1 OYUGBGZDLCAQEA-UHFFFAOYSA-N 0.000 claims 1
- VLJUOFGVEJAFFK-UHFFFAOYSA-N 6-(2,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC2=CC(O)=CC=C2C=C1C1=CC(F)=C(O)C=C1F VLJUOFGVEJAFFK-UHFFFAOYSA-N 0.000 claims 1
- DZGRIHNLLUZLTL-UHFFFAOYSA-N 6-(3,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC2=CC(O)=CC=C2C=C1C1=CC(F)=C(O)C(F)=C1 DZGRIHNLLUZLTL-UHFFFAOYSA-N 0.000 claims 1
- YIKDKHNOMWERET-UHFFFAOYSA-N 6-(4-hydroxy-2-methylphenyl)naphthalen-2-ol Chemical compound CC1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1 YIKDKHNOMWERET-UHFFFAOYSA-N 0.000 claims 1
- MBESMLNJQCOTRU-UHFFFAOYSA-N 6-(4-hydroxyphenyl)naphthalen-1-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C(O)=CC=C2)C2=C1 MBESMLNJQCOTRU-UHFFFAOYSA-N 0.000 claims 1
- PZOXFBPKKGTQDZ-UHFFFAOYSA-N 6-phenylnaphthalen-2-ol Chemical compound C1=CC2=CC(O)=CC=C2C=C1C1=CC=CC=C1 PZOXFBPKKGTQDZ-UHFFFAOYSA-N 0.000 claims 1
- TYSOZDHVMFAZKD-UHFFFAOYSA-N 8-fluoro-6-(3-fluoro-4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=C(F)C2=CC(O)=CC=C2C=C1C1=CC=C(O)C(F)=C1 TYSOZDHVMFAZKD-UHFFFAOYSA-N 0.000 claims 1
- 206010002652 Anorgasmia Diseases 0.000 claims 1
- 206010016344 Feeling of despair Diseases 0.000 claims 1
- 206010038743 Restlessness Diseases 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 230000001720 vestibular Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 35
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 79
- 241000700159 Rattus Species 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 22
- 238000011282 treatment Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 14
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 12
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 12
- 229950002007 estradiol benzoate Drugs 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229960003638 dopamine Drugs 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 230000000971 hippocampal effect Effects 0.000 description 10
- 230000006742 locomotor activity Effects 0.000 description 10
- 230000020796 long term synaptic depression Effects 0.000 description 10
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 10
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- BAAILVWEAXFTSF-UHFFFAOYSA-N chembl188528 Chemical compound C1=CC(O)=CC=C1C1=NC2=CC(O)=CC(Br)=C2O1 BAAILVWEAXFTSF-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229960005309 estradiol Drugs 0.000 description 8
- 230000013016 learning Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 7
- 229960004046 apomorphine Drugs 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 6
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 6
- 208000028017 Psychotic disease Diseases 0.000 description 6
- 230000009194 climbing Effects 0.000 description 6
- 230000027928 long-term synaptic potentiation Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 208000027061 mild cognitive impairment Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000003956 synaptic plasticity Effects 0.000 description 5
- 208000009132 Catalepsy Diseases 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 206010047853 Waxy flexibility Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229940025084 amphetamine Drugs 0.000 description 4
- 239000000164 antipsychotic agent Substances 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 206010012374 Depressed mood Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010042008 Stereotypy Diseases 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 229950011260 betanaphthol Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000024732 dysthymic disease Diseases 0.000 description 3
- 230000001073 episodic memory Effects 0.000 description 3
- 238000009164 estrogen replacement therapy Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007107 neurocognitive deficit Effects 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 201000003104 endogenous depression Diseases 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical group Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 230000000848 glutamatergic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000036403 neuro physiology Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000013439 planning Methods 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000003977 synaptic function Effects 0.000 description 2
- 230000008625 synaptic signaling Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 0 *C1=C(*)c(c(*)c(*)cc2*)c2N[C@]1C(C=C)=CC=* Chemical compound *C1=C(*)c(c(*)c(*)cc2*)c2N[C@]1C(C=C)=CC=* 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- AHFMSNDOYCFEPH-UHFFFAOYSA-N 1,2-difluoroethane Chemical compound FCCF AHFMSNDOYCFEPH-UHFFFAOYSA-N 0.000 description 1
- UPPYOQWUJKAFSG-UHFFFAOYSA-N 1,3-benzoxazol-5-ol Chemical compound OC1=CC=C2OC=NC2=C1 UPPYOQWUJKAFSG-UHFFFAOYSA-N 0.000 description 1
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- XLPIEPJJDJBOFU-UHFFFAOYSA-N 3-(5-methyl-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=CC=1CCC(O)=O XLPIEPJJDJBOFU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 description 1
- OUXCXNNATUONBL-UHFFFAOYSA-N 4-(7-bromo-1,3-benzoxazol-2-yl)phenol Chemical compound BrC1=CC=CC=2N=C(OC=21)C1=CC=C(C=C1)O OUXCXNNATUONBL-UHFFFAOYSA-N 0.000 description 1
- KDXFAXLIFJHOEU-UHFFFAOYSA-N 4-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol Chemical compound C1=CC(=CC=C1C2=NC3=C(O2)C=CC(=C3Br)O)O KDXFAXLIFJHOEU-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012259 Delusional symptoms Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 229940127406 Estrogen Receptor Agonists Drugs 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 206010066392 Fear of death Diseases 0.000 description 1
- 206010016754 Flashback Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 206010027925 Monoparesis Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000032369 Primary transmission Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000019194 Sorbus aucuparia Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001090 anti-dopaminergic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000020538 atrophic muscular disease Diseases 0.000 description 1
- 230000009901 attention process Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012926 crystallographic analysis Methods 0.000 description 1
- 210000003464 cuspid Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 229960003135 donepezil hydrochloride Drugs 0.000 description 1
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000014061 fear response Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
- 230000008801 hippocampal function Effects 0.000 description 1
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000007595 memory recall Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007106 neurocognition Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- AZHVQJLDOFKHPZ-UHFFFAOYSA-N oxathiazine Chemical compound O1SN=CC=C1 AZHVQJLDOFKHPZ-UHFFFAOYSA-N 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960004323 rivastigmine tartrate Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 235000006414 serbal de cazadores Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- YYMWVZQRBNARFZ-UHFFFAOYSA-M sodium;2-[2,3-bis(sulfanyl)propoxy]ethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCOCC(S)CS YYMWVZQRBNARFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000007596 spatial working memory Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 206010047385 vestibular ataxia Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000009184 walking Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63714404P | 2004-12-17 | 2004-12-17 | |
| PCT/US2005/045375 WO2006065968A2 (en) | 2004-12-17 | 2005-12-15 | The uses of estrogen beta agonists to treat cognitive diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524236A true JP2008524236A (ja) | 2008-07-10 |
| JP2008524236A5 JP2008524236A5 (cg-RX-API-DMAC7.html) | 2009-02-05 |
Family
ID=36143266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007546887A Pending JP2008524236A (ja) | 2004-12-17 | 2005-12-15 | エストロゲンβアゴニストについての新規用途 |
Country Status (20)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020512384A (ja) * | 2017-03-30 | 2020-04-23 | マーケット ユニバーシティー | 置換(4’−ヒドロキシフェニル)シクロアルカンおよび(4’−ヒドロキシフェニル)シクロアルケン化合物ならびに記憶固定を向上させるためのエストロゲン受容体βアイソフォームの選択的アゴニストとしてのそれらの使用方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1984028A2 (en) * | 2006-02-14 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Aqueous pharmaceutical formulations of er selective ligands |
| WO2010105035A2 (en) * | 2009-03-11 | 2010-09-16 | University Of South Florida | Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure |
| US10149982B2 (en) | 2009-03-11 | 2018-12-11 | University Of South Florida | Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment |
| US10758496B2 (en) * | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003050095A1 (en) * | 2001-12-05 | 2003-06-19 | Wyeth | Substituted benzoxazoles and analogues as estrogenic agents |
| WO2003051863A1 (en) * | 2001-12-13 | 2003-06-26 | Wyeth | SUBSTITUTED 6H-DIBENZO[c,h]CHROMENES AS ESTROGENIC AGENTS |
| WO2003051860A2 (en) * | 2001-12-18 | 2003-06-26 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| WO2003051805A2 (en) * | 2001-12-13 | 2003-06-26 | Wyeth | Substituted phenyl naphthalenes as estrogenic agents |
| WO2004026290A1 (en) * | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Method for treating depression and/or anxiety |
| WO2004103973A1 (en) * | 2003-05-16 | 2004-12-02 | Wyeth | Phenyl quinolines and their use as estrogen receptor modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990078A (en) * | 1995-07-14 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Means of increasing estrogen receptor levels in neural tissue |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| WO1998021946A1 (en) * | 1996-11-18 | 1998-05-28 | Internutria, Inc. | Composition and treatment for persistent reproductive transition symptoms |
| US20040092010A1 (en) * | 2002-04-15 | 2004-05-13 | Ariel Ruiz I Altaba | Method of proliferating and inducing brain stem cells to differentiate to neurons |
| TR200102992T2 (tr) * | 1999-04-16 | 2004-12-21 | Astrazeneca Ab | ß östrojen reseptörü ligandları. |
| JP2004515496A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| US20030096264A1 (en) * | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| DE60116109T2 (de) * | 2001-11-07 | 2006-09-07 | Schering Ag | In vitro Screening nach Liganden des Östrogenrezeptors |
| US7157492B2 (en) * | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| JP2008505095A (ja) * | 2004-07-01 | 2008-02-21 | ワイス | エストロゲンリガンドとしての四環式化合物 |
-
2005
- 2005-12-15 RU RU2007120254/14A patent/RU2007120254A/ru not_active Application Discontinuation
- 2005-12-15 EP EP05854149A patent/EP1824478A2/en not_active Withdrawn
- 2005-12-15 MX MX2007007347A patent/MX2007007347A/es unknown
- 2005-12-15 US US11/304,037 patent/US20060135574A1/en not_active Abandoned
- 2005-12-15 KR KR1020077013666A patent/KR20070086329A/ko not_active Withdrawn
- 2005-12-15 AR ARP050105297A patent/AR051844A1/es unknown
- 2005-12-15 TW TW094144391A patent/TW200637545A/zh unknown
- 2005-12-15 AU AU2005316561A patent/AU2005316561A1/en not_active Abandoned
- 2005-12-15 CN CNA2005800434508A patent/CN101321524A/zh active Pending
- 2005-12-15 BR BRPI0519111-4A patent/BRPI0519111A2/pt not_active IP Right Cessation
- 2005-12-15 PA PA20058656601A patent/PA8656601A1/es unknown
- 2005-12-15 CA CA002590258A patent/CA2590258A1/en not_active Abandoned
- 2005-12-15 JP JP2007546887A patent/JP2008524236A/ja active Pending
- 2005-12-15 GT GT200500370A patent/GT200500370A/es unknown
- 2005-12-15 WO PCT/US2005/045375 patent/WO2006065968A2/en not_active Ceased
-
2006
- 2006-01-03 PE PE2006000026A patent/PE20061113A1/es not_active Application Discontinuation
-
2007
- 2007-05-24 NO NO20072658A patent/NO20072658L/no not_active Application Discontinuation
- 2007-05-31 IL IL183604A patent/IL183604A0/en unknown
- 2007-06-14 NI NI200700152A patent/NI200700152A/es unknown
- 2007-06-15 ZA ZA200705103A patent/ZA200705103B/xx unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003050095A1 (en) * | 2001-12-05 | 2003-06-19 | Wyeth | Substituted benzoxazoles and analogues as estrogenic agents |
| WO2003051863A1 (en) * | 2001-12-13 | 2003-06-26 | Wyeth | SUBSTITUTED 6H-DIBENZO[c,h]CHROMENES AS ESTROGENIC AGENTS |
| WO2003051805A2 (en) * | 2001-12-13 | 2003-06-26 | Wyeth | Substituted phenyl naphthalenes as estrogenic agents |
| WO2003051860A2 (en) * | 2001-12-18 | 2003-06-26 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| WO2004026290A1 (en) * | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Method for treating depression and/or anxiety |
| WO2004103973A1 (en) * | 2003-05-16 | 2004-12-02 | Wyeth | Phenyl quinolines and their use as estrogen receptor modulators |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020512384A (ja) * | 2017-03-30 | 2020-04-23 | マーケット ユニバーシティー | 置換(4’−ヒドロキシフェニル)シクロアルカンおよび(4’−ヒドロキシフェニル)シクロアルケン化合物ならびに記憶固定を向上させるためのエストロゲン受容体βアイソフォームの選択的アゴニストとしてのそれらの使用方法 |
| JP2023085342A (ja) * | 2017-03-30 | 2023-06-20 | マーケット ユニバーシティー | 置換(4’-ヒドロキシフェニル)シクロアルカンおよび(4’-ヒドロキシフェニル)シクロアルケン化合物ならびに記憶固定を向上させるためのエストロゲン受容体βアイソフォームの選択的アゴニストとしてのそれらの使用方法 |
| JP2025081398A (ja) * | 2017-03-30 | 2025-05-27 | マーケット ユニバーシティー | 置換(4’-ヒドロキシフェニル)シクロアルカンおよび(4’-ヒドロキシフェニル)シクロアルケン化合物ならびに記憶固定を向上させるためのエストロゲン受容体βアイソフォームの選択的アゴニストとしてのそれらの使用方法 |
| JP7708379B2 (ja) | 2017-03-30 | 2025-07-15 | マーケット ユニバーシティー | 置換(4’-ヒドロキシフェニル)シクロアルカンおよび(4’-ヒドロキシフェニル)シクロアルケン化合物ならびに記憶固定を向上させるためのエストロゲン受容体βアイソフォームの選択的アゴニストとしてのそれらの使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0519111A2 (pt) | 2008-12-23 |
| CN101321524A (zh) | 2008-12-10 |
| PA8656601A1 (es) | 2006-12-07 |
| AR051844A1 (es) | 2007-02-14 |
| WO2006065968A8 (en) | 2008-09-12 |
| IL183604A0 (en) | 2007-10-31 |
| AU2005316561A1 (en) | 2006-06-22 |
| MX2007007347A (es) | 2007-07-13 |
| RU2007120254A (ru) | 2009-01-27 |
| NO20072658L (no) | 2007-09-12 |
| WO2006065968A2 (en) | 2006-06-22 |
| PE20061113A1 (es) | 2006-11-06 |
| CA2590258A1 (en) | 2006-06-22 |
| WO2006065968A3 (en) | 2008-04-10 |
| TW200637545A (en) | 2006-11-01 |
| GT200500370A (es) | 2006-07-13 |
| NI200700152A (es) | 2008-06-17 |
| KR20070086329A (ko) | 2007-08-27 |
| EP1824478A2 (en) | 2007-08-29 |
| ZA200705103B (en) | 2009-11-25 |
| US20060135574A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101939017B (zh) | 大麻素在与抗精神病药物组合中的用途 | |
| Mihic et al. | Hypnotics and sedatives | |
| OA12554A (en) | Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. | |
| AU2007240469B2 (en) | Pharmacological modulation of positive AMPA receptor modulator effects on neurotrophin expression | |
| WO2015032966A1 (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
| EP2714040A1 (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| US20200016163A1 (en) | Treatment of dementia with cannabinoid agonists | |
| JP5259181B2 (ja) | うつ病または不安神経症の予防または治療剤 | |
| US20060135574A1 (en) | Novel uses for estrogen beta agonists | |
| JP2008512440A (ja) | ジアザビシクロ化合物含有ベンゾイソオキサゾールを用いる気分障害の治療方法 | |
| EP2792359A1 (en) | Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712 | |
| WO2013152108A1 (en) | 5ht1a agonist for treatment of high cholesterol | |
| JP2022507947A (ja) | 勃起不全のための方法および処置 | |
| Siembida et al. | GHB receptors-a new trend in psychopharmacology? | |
| WO2007004226A2 (en) | Compositions and methods for treatment of male erectile dysfunction (ed) | |
| HK1186416A (en) | Use of cannabinoids in combination with aripiprazole | |
| SACHIN | Master of Veterinary Science |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110726 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120124 |